Delineation of prognostic biomarkers in prostate cancer (original) (raw)

References

  1. Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410–2434 (2000).
    Article CAS Google Scholar
  2. Ruijter, E. et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 20, 22–45 (1999).
    Article CAS Google Scholar
  3. Barry, M. J. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344, 1373–1377 (2001).
    Article CAS Google Scholar
  4. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48–56 (2000).
    Article CAS Google Scholar
  5. Elek, J., Park, K. H. & Narayanan, R. Microarray-based expression profiling in prostate tumors. In Vivo 14, 173–182 (2000).
    CAS PubMed Google Scholar
  6. Emmert-Buck, M. R. et al. Molecular profiling of clinical tissue specimens: feasibility and applications. Am. J. Pathol. 156, 1109–1115 (2000).
    Article CAS Google Scholar
  7. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
    Article CAS Google Scholar
  8. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540 (2000).
    Article ADS CAS Google Scholar
  9. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
    Article ADS CAS Google Scholar
  10. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
    Article ADS CAS Google Scholar
  11. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863–14868 (1998).
    Article ADS CAS Google Scholar
  12. Tomita, K. et al. Cadherin switching in human prostate cancer progression. Cancer Res. 60, 3650–3654 (2000).
    CAS PubMed Google Scholar
  13. Shurbaji, M. S., Kalbfleisch, J. H. & Thurmond, T. S. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 27, 917–921 (1996).
    Article CAS Google Scholar
  14. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 4, 844–847 (1998).
    Article CAS Google Scholar
  15. Perrone, E. E. et al. Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J. Natl Cancer. Inst. 92, 937–939 (2000).
    Article CAS Google Scholar
  16. Tsuji, A. et al. Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J. Biol. Chem. 266, 16948–16953 (1991).
    CAS PubMed Google Scholar
  17. Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. Jama 281, 1591–1597 (1999).
    Article CAS Google Scholar
  18. Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 23, 273–279 (1992).
    Article CAS Google Scholar
  19. Buttyan, R., Sawczuk, I. S., Benson, M. C., Siegal, J. D. & Olsson, C. A. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11, 327–337 (1987).
    Article CAS Google Scholar
  20. Rubin, M. A. et al. Rapid (‘warm’) autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6, 1036–10345 (2000).
    Google Scholar

Download references

Acknowledgements

We are indebted to P. Ward and the University of Michigan Microarray Network for support and encouragement in the development of the Pathology Microarray Node. We thank M. Sanda and J. Wei for support of the clinical database; E. Cushenberry for her help with collecting the prostate tissue samples, The University of Michigan Comprehensive Cancer Center Histology and Immunoperoxidase Core; and the instructors of the 1999 Cold Spring Harbor Workshop on DNA Microarrays. This work is supported by developmental grants (A.M.C. and M.A.R.) from the Specialized Program of Research Excellence in Prostate Cancer, National Cancer Institute.

Author information

Author notes

  1. Mark A. Rubin and Arul M. Chinnaiyan: These authors share senior authorship

Authors and Affiliations

  1. Department of Pathology, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Saravana M. Dhanasekaran, Terrence R. Barrette, Rajal Shah, Sooryanarayana Varambally, Mark A. Rubin & Arul M. Chinnaiyan
  2. Department of Biostatistics, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Debashis Ghosh
  3. Department of Human Genetics, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Kotoku Kurachi
  4. Department of Urology, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Kenneth J. Pienta, Mark A. Rubin & Arul M. Chinnaiyan
  5. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Kenneth J. Pienta
  6. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor,, 48109, Michigan, USA
    Kenneth J. Pienta, Mark A. Rubin & Arul M. Chinnaiyan

Authors

  1. Saravana M. Dhanasekaran
    You can also search for this author inPubMed Google Scholar
  2. Terrence R. Barrette
    You can also search for this author inPubMed Google Scholar
  3. Debashis Ghosh
    You can also search for this author inPubMed Google Scholar
  4. Rajal Shah
    You can also search for this author inPubMed Google Scholar
  5. Sooryanarayana Varambally
    You can also search for this author inPubMed Google Scholar
  6. Kotoku Kurachi
    You can also search for this author inPubMed Google Scholar
  7. Kenneth J. Pienta
    You can also search for this author inPubMed Google Scholar
  8. Mark A. Rubin
    You can also search for this author inPubMed Google Scholar
  9. Arul M. Chinnaiyan
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toArul M. Chinnaiyan.

Supplementary information

Supplemental Figure 1

Same as Fig. 1b of the manuscript except for depiction of dendrograms for gene expression.

Supplemental Figure 2

Same as Fig. 1c of the manuscript except for depiction of dendrograms for gene expression.

Supplemental Figure 3

Comparison of normal adjacent prostate tissue (NAP) with the normal prostate tissue reference (CP). The same convention for representing changes in transcript levels was used as in Fig. 1 of the manuscript. The cluster was obtained by selecting for genes with at least a 2.5-fold variation in any two of the samples of each class, namely the normal tissues versus the NAP pool and normal tissue versus the CP pool at a 50% filter. Of the genes analyzed 59 were selected with this criteria. Genes that were found to be up-regulated in the NAP pool in comparison with CP pool, included connective tissue growth factor, EGR-1 (Early Growth Response 1), matrilysin (MMP7), CFLAR/I-FLICE (caspase 8 and FADD-like apoptosis regulator), lumican, serum glucocorticoid regulated kinase, lens epithelium derived growth factor, PAI1 (plasminogen activator inhibitor type I), JUN and FOS B, among others. Vascular endothelial growth factor (VEGF), growth arrest specific (GAS1), cholecystokinin (CCK), amiloride binding protein (ABP1) were among the down-regulated genes in the normal adjacent prostate pool when compared to the commercial pool. The gene expression differences between normal prostate adjacent to PCA (NAP) and normal prostate tissue from individuals without prostate pathology (CP) may be attributable to a "field effect" induced by PCA itself.

Supplementary Figure 4

A focused cluster of PCA-related genes. The same convention for representing changes in transcript levels was used as in Fig. 1 of the manuscript. This cluster of 231 genes was generated by selecting for a 3.5-fold variation in at least 2 of any class, and ratio measurements present in 75% of the samples. Classes included: PCA vs. NAP, MET vs. NAP, PCA vs. CP and MET vs. CP.

Supplemental Figure 5

Gene selection based on computed t-statistics for each gene. Two groups were used in the analysis: PCA/MET and benign (NAP/BPH). a, Analysis of NAP pool data. b, Analysis of CP pool data. Selected genes are named and 200 genes for each data set are shown. Refer to manuscript text for formal statistical method. Gene selection based on each method is included as a supplementary text file. Selected gene names or symbols (as specified by Human genome organization (HUGO) gene nomenclature) are shown.

Supplemental Figure 6

Functional clusters of select genes differentially expressed in prostate cancer. Gene names or symbols (as specified by Human genome organization (HUGO) gene nomenclature) are shown. The same convention for representing changes in transcript levels was used as in Fig.1. The sample order from Fig.1 was preserved for clarity.

Supplemental Figure 7

"Executive Summary." Representative genes differentially expressed in PCA identified by DNA microarray analysis. Genes are grouped functionally and arrows represent up- or down- regulation in metastatic hormone-refractory PCA (MET) and/or localized PCA (PCA) relative to normal prostate epithelium. See Fig.2 of the manuscript for gene expression levels. The following paragraphs refer to descriptions of and hypotheses generated from our gene expression profiling of PCA. Gene names or symbols (as specified by Human genome organization (HUGO) gene nomenclature) are shown.

Supplemental Figure 8

Additional prostate tissue specimens profiled against a commercial prostate reference pool (CPP). The same convention for representing changes in transcript level was used as in Figure 1 of the manuscript. A total of 53 prostate specimens were profiled against the commercial pool. They include, 4 normal adjacent prostate tissue (NAP), 14 benign prostatic hyperplasia (BPH), 1 prostatitis, 14 localized prostate cancer (PCA) and 20 hormone refractory metastatic PCA (MET). Prior to hierarchial average-linkage clustering, the data was filtered for at least 3-fold change in Cy5/Cy3 ratios and measurements present in 75% of the samples. By this method 1325 genes were selected. This figure expands on Figure 1c with an additional 40 samples, which include all from Figure 1b, and also includes 28 additional prostate specimens.

Data 1b

Data 1c

Data 3

Data 4

Data 5

Data 8

Table 1: Patient samples used in this study, and Supplementary methods

Rights and permissions

About this article

Cite this article

Dhanasekaran, S., Barrette, T., Ghosh, D. et al. Delineation of prognostic biomarkers in prostate cancer.Nature 412, 822–826 (2001). https://doi.org/10.1038/35090585

Download citation